Edit |   |
---|---|
Antigenic Specificity | PD-L1/PDCD1LG1/CD274/B7-H1 (Cancer Immunotherapy Target) |
Clone | [PDL1/2741] |
Host Species | Mouse |
Reactive Species | human |
Isotype | IgG1, kappa |
Format | purified |
Size | 0.02 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (Without BSA & Azide at 1mg/ml) |
Concentration | n/a |
Applications | ELISA (EIA) |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Specificity: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
Immunogen | Immunogen: Recombinant fragment of human CD274 protein (around aa39-191) (exact sequence is proprietary) |
Other Names | [B7 homolog 1; B7-H1; CD274; PD-L1; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; Programmed cell death 1 ligand 1] |
Gene, Accession # | [CD274], Gene ID: 29126, NCBI: NP_001254635.1, UniProt: Q9NZQ7 |
Catalog # | MBS4380955 |
Price | $190, $340, $340 |
Order / More Info | PD-L1/PDCD1LG1/CD274/B7-H1 (Cancer Immunotherapy Target) Antibody from MYBIOSOURCE INC. |
Product Specific References | Dong, H., et al. 1999. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5: 1365-1369 |